ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SNDX Syndax Pharmaceuticals Inc

13.20
0.40 (3.13%)
Pre Market
Last Updated: 09:02:08
Delayed by 15 minutes
Share Name Share Symbol Market Type
Syndax Pharmaceuticals Inc NASDAQ:SNDX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.40 3.13% 13.20 12.80 13.98 475 09:02:08

Syndax Announces Participation at the Citi 2024 Global Healthcare Conference

27/11/2024 12:00pm

PR Newswire (US)


Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart


From Nov 2024 to Jan 2025

Click Here for more Syndax Pharmaceuticals Charts.

WALTHAM, Mass., Nov. 27, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a panel discussion on novel mechanisms in oncology at the Citi 2024 Global Healthcare Conference on Thursday, December 5, 2024 at 11:00 a.m. ET.

A live webcast of the panel can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.

Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

Cision View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-the-citi-2024-global-healthcare-conference-302316980.html

SOURCE Syndax Pharmaceuticals, Inc.

Copyright 2024 PR Newswire

1 Year Syndax Pharmaceuticals Chart

1 Year Syndax Pharmaceuticals Chart

1 Month Syndax Pharmaceuticals Chart

1 Month Syndax Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock